Forget coronavirus penny stocks! I think there’s an easier way to get rich

Penny stocks related to the pandemic have made lots of money over the past few months but this Fool remains wary.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The massive rebound in markets over the past few months has seen a lot of new investors signing up for a slice of the action. And who can really blame them when you have many coronavirus-related penny stocks multi-bagging in value?

Is this an easy route to riches? Probably not, and here’s why.  

The problem with penny stocks

Now, don’t get me wrong: you certainly can become very wealthy if you buy the right minnows at the right time. But there’s the rub – identifying penny share winners and timing your purchases early enough is fiendishly difficult given the huge number of factors that determine whether a company succeeds or not. A potentially great business doesn’t always translate to a great investment. 

As well as being hard to sort the wheat from the chaff, those wanting to invest in this part of the market must also be aware of how ‘illiquid’ penny stocks can be. Liquidity means how easy it is to buy or sell something without affecting its price. Illiquidity can be great when the herd wants to buy (causing shares to jump) but a nightmare when everyone sprints to the exit. Forced sellers must often accept prices that, in normal circumstances, they would laugh at. 

The huge volatility seen in penny stocks is worth remembering right now. It would be wrong to assume that many of those coronavirus-linked stocks that have soared over the past few months won’t suddenly tumble in value. This may be due to another broad market crash, traders banking profits, or news that the products they supply are no longer needed or ineffective.

It doesn’t stop there with penny stock drawbacks. Young companies, particularly those in high-risk, high-reward sectors, often need to tap the market for more cash just to keep the lights on. Sadly, this isn’t always forthcoming and many are forced to fold, making the shares worthless.  

Make no mistake, penny stocks can make you rich but they’re also far more likely to leave you poor.

A better solution

Rather than attempt to find the needle in a haystack, there are other, safer ways of tapping into healthcare or biotechnology.

For the former, you could always buy a FTSE 100 juggernaut like AstraZeneca or GlaxoSmithKline. For the latter, you can buy active funds that specialise in this part of the market. Two of the most popular are Biotech Growth Trust (LSE: BIOG) and International Biotechnology Trust (LSE: IBT). 

Another option is to buy passive funds that focus on these themes. Like their active equivalents, these give instant diversification to holders by investing in a large number of stocks. And since they’re only out to track rather than beat indexes, the fees are a lot lower.

Examples include the iShares Healthcare Innovation UCITS ETF. The iShares Ageing Population UCITS ETF, which gives exposure to companies providing products and services to those in their golden years (many of which will be healthcare-related), is also worth considering. Both funds have ongoing charges of just 0.4%. 

Bottom line

A punt on coronavirus-related penny stocks might make you rich but there’s a very real chance it will go wrong. If you’re tempted, I’d suggest only using money you can afford to lose. Put the majority of your capital to work in far less risky options. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

This 10.6% yielder beats every dividend share on the FTSE 100. Can it last?

Harvey Jones couldn't resist the double-digit yield on offer from this FTSE 100 stock. Now he'd like to get some…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

With the FTSE 100 flying, I love the look of this company

The FTSE 100 index has been in rally mode over the last few months, but I think one of it's…

Read more »

Investing Articles

17% of my Stocks and Shares ISA is invested in these 2 UK shares

Stephen Wright looks to focus on investments in companies that have strong competitive advantages. And two UK shares stand out…

Read more »

Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA into Lloyds shares

Harvey Jones bought Lloyds shares last year and is kicking himself for failing to buy even more of them. The…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Apple is still my favourite company in the S&P 500, here’s why

Apple recently unveiled a lot of new software at a developer conference. Here's why the tech giant is still my…

Read more »

Investing Articles

5 great value UK companies I’d buy in a Stocks and Shares ISA and aim to hold for decades 

Harvey Jones is getting to work on his Stocks and Shares ISA. He thinks these five firms have solid income…

Read more »

Value Shares

Are GSK shares a bargain after falling 11%?

GSK shares have taken a hit in recent weeks due to Zantac uncertainty. Here, Edward Sheldon looks at whether they’re…

Read more »

Investing Articles

Nearing £5, could the Rolls-Royce share price hit £6?

The Rolls-Royce share price has soared in the past year. Our writer thinks there could be a strong runway ahead…

Read more »